Abstract:The ability to use in vitro human cytochrome P450 (CYP) time-dependent inhibition (TDI) data for in vivo drug-drug interaction (DDI) predictions should be viewed as a prerequisite to generating the data. Important terms in making such predictions are k(inact) and K(I) but first-line screening assays typically involve characterisation of an IC(50) value or a time dependent shift in IC(50). In the work presented here, two key screening methods from the scientific literature were appraised both in terms of practicality and quality of k(inact)/K(I) estimation. The utility of TDI screening data in DDI predictions was investigated and particular reference given to a simple DDI simulation model based on a spreadsheet that calculates the systemic exposure of unbound inhibitor drug following the input of human pharmacokinetic parameters. Using several clinical mechanism-based CYP DDI examples, the effectiveness of the approach was assessed and compared to other widely available approaches (a simple algorithm that employs a single in vivo unbound inhibitor concentration, a seven-compartment physiologically based pharmacokinetic (PBPK) model that defines the extent of interaction as a result of hepatic inhibitor concentrations and the commercially available software SimCYP). All the methods gave predictions that compared favourably with the observed DDIs, but various advantages and disadvantages of each were also given full consideration. The new model facilitates rapid sensitivity analysis (parameters can be easily input and altered to give a visual representation of the impact on the active enzyme concentration) and it was therefore used to derive "rules of thumb" demonstrating the relationship between extent of DDI, time-dependent IC(50) and dose for typical acidic and basic drugs. Additionally, a TDI decision tree linking into reactive metabolite investigations is proposed for use in a Drug Discovery setting.

A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment

Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic

Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches

In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drug–Drug Interactions

Review of Drug Interactions Mechanism Based on Cytochrome P450s

CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications

CYP450 Induction Based Drug-Drug Interaction and Evaluation Methodology

Prediction of Cytochrome 450 Mediated Drug-Drug Interactions by Three-Dimensional Cultured Hepatocytes

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice

Understanding and preventing drug–drug and drug–gene interactions

Application of Mechanism-Based CYP Inhibition for Predicting Drug–drug Interactions

In Silico Methods for Predicting Drug–drug Interactions with Cytochrome P-450s, Transporters and Beyond

Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation

Clinical Drug–Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access

Herb–Drug, Food–Drug, Nutrient–Drug, and Drug–Drug Interactions: Mechanisms Involved and Their Medical Implications

Metabolite Measurement in Index Substrate Drug Interaction Studies: A Review of the Literature and Recent New Drug Application Reviews

Are Circulating Metabolites Important in Pharmacokinetic Drug-Drug Interactions? A Retroanalysis of Clinical Data

Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods

Innovative Approaches to Optimize Clinical Transporter Drug-Drug Interaction Studies

Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications